LDN-57444 sensitizes hepatocellular carcinoma cells to sorafenib by promoting ferroptosis through histone deacetylase 2 (HDAC2) inhibition.

Saved in:
Bibliographic Details
Title: LDN-57444 sensitizes hepatocellular carcinoma cells to sorafenib by promoting ferroptosis through histone deacetylase 2 (HDAC2) inhibition.
Authors: Lin JC; Department of Surgery, MacKay Memorial Hospital, Taipei, 104217, Taiwan.; MacKay Junior College of Medicine, Nursing and Management, New Taipei City, 112021, Taiwan.; Department of Medicine, MacKay Medical University, New Taipei City, 252005, Taiwan.; Liver Medical Center, MacKay Memorial Hospital, Taipei, 104217, Taiwan.; Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, 110301, Taiwan., Huang TS; Department of Surgery, MacKay Memorial Hospital, Taipei, 104217, Taiwan.; Department of Medicine, MacKay Medical University, New Taipei City, 252005, Taiwan.; Liver Medical Center, MacKay Memorial Hospital, Taipei, 104217, Taiwan., Chen YB; Department of Surgery, MacKay Memorial Hospital, Taipei, 104217, Taiwan., Chen TY; Department of Pathology, MacKay Memorial Hospital, Taipei, 104217, Taiwan., Wu PS; Department of Anatomical Pathology, Far Eastern Memorial Hospital, New Taipei City, 220216, Taiwan., Liu TP; Department of Surgery, MacKay Memorial Hospital, Taipei, 104217, Taiwan.; MacKay Junior College of Medicine, Nursing and Management, New Taipei City, 112021, Taiwan.; Department of Medicine, MacKay Medical University, New Taipei City, 252005, Taiwan.; Liver Medical Center, MacKay Memorial Hospital, Taipei, 104217, Taiwan.; Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, 110301, Taiwan., Yang PM; Liver Medical Center, MacKay Memorial Hospital, Taipei, 104217, Taiwan. yangpm@tmu.edu.tw.; Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, 110301, Taiwan. yangpm@tmu.edu.tw.; Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, 110301, Taiwan. yangpm@tmu.edu.tw.; TMU Research Center of Cancer Translational Medicine, Taipei, 110301, Taiwan. yangpm@tmu.edu.tw.; Cancer Center, Wan Fang Hospital, Taipei Medical University, Taipei, 116079, Taiwan. yangpm@tmu.edu.tw.; TMU and Affiliated Hospitals Pancreatic Cancer Groups, Taipei Medical University, Taipei, 110301, Taiwan. yangpm@tmu.edu.tw.; Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, 301 Yuantong Rd., Zhonghe Dist, New Taipei City, 235603, Taiwan. yangpm@tmu.edu.tw.
Source: Biology direct [Biol Direct] 2026 Feb 13; Vol. 21 (1). Date of Electronic Publication: 2026 Feb 13.
Publication Type: Journal Article
Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 101258412 Publication Model: Electronic Cited Medium: Internet ISSN: 1745-6150 (Electronic) Linking ISSN: 17456150 NLM ISO Abbreviation: Biol Direct Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1745-6150
DOI:10.1186/s13062-026-00735-1